Yifan Pharmaceutical (002019.SZ): Vinblastine sulfate injection drug registration and marketing license application accepted for domestically produced drugs

Zhitongcaijing · 3d ago

Zhitong Finance App News, Yifan Pharmaceutical (002019.SZ) issued an announcement. On November 4, 2026, Hefei Yifan Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Acceptance” issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”) for registration and marketing of vinblastine sulfate injection domestically produced drugs.

Vinblastine sulfate injection is suitable for palliative treatment of the following conditions: It is mainly suitable for the treatment of highly sensitive malignancies (extensive Hodgkin lymphoma, lymphocytic lymphoma, histiocytic lymphoma, etc.) and low-sensitivity malignancies (choriocarcinoma resistant to other chemotherapy, breast cancer where endocrine surgery and hormone therapy are not effective).